Castro J, Puente P, Martínez R, Valdés I, Gil L, Guillén G, Morera Y, Bello I, Cosme K, Hernández A, Martínez L, Aldana L, Pichardo D, Ayala M, Lazo L, Hermida L, Suzarte E, Romero Y

Language: Spanish
References: 96
Page: 4501-4512
PDF size: 491.60 Kb.

ABSTRACT

The body weight and the characterization of the hematological, hemochemical and histopathological parameters of the non-human primate Chlorocebus aethiops sabaeus (African green monkey) were characterized, together with its usefulness as animal model in biomedicine. The study was aimed for making available a NHP species on its Caribbean subspecies, easy to handle and of numerous Population which facilitates its use in biomedicine and for the biopharmaceutical industry. The physiologic range of body weight and the main hematological and hemochemical parameters were set for the different age groups and both sexes of healthy NHP C. aethiops subspecies kept under experimental conditions. Moreover, it was studied their capacity for the replication of Dengue virus serotype 2 and the performance of the analyzed parameters following the administration of three biotechnological products against cancer. The social and economic impact of this research are supported by the availability of the anthropometric characteristics for the species, as reference material for future research. This work received the Annual Award of the Cuban Academy of Sciences for the year 2018.

REFERENCES

1. Vilensky JA. Am J Physiol Anthropol. 1988;75(2):283-4.

2. Fujiyama A, Watanabe H, Toyoda A, Taylor TD, Itoh T, Tsai SF, et al. Construction and analysis of a human-chimpanzee comparative clone map. Science. 2002;295(5552):131-4.

3. EMEA/CPMP/1100/02. Note for guidance on the development of vaccinia virus based vaccines against smallpox. 2002.

4. Ward KW, Coon DJ, Magiera D, Bhadresa S, Nisbett E, Lawrence MS. Exploration of the African green monkey as a preclinical pharmacokinetic model: intravenous pharmacokinetic parameters. Drug Metab Dispos. 2008;36(4):715-20.

5. Arteaga ME, Ledón N, Casacó A, Pardo B, García M, Boleda M, et al. Systemic and skin toxicity in Cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the antiepidermal growth factor receptor monoclonal antibody nimotuzumab. Cancer Biol Ther. 2007;6(9):1390-5.

6. Coe CL, Savage A, Bromley LJ. Phylogenetic influences on hormone levels across the primate order. Am J Primatol. 1992;28:81-100.

7. Fainman J, Eid MD, Ervin FR, Palmour RM. A primate model for Alzheimer’s disease: investigation of the apolipoprotein E profile of the vervet monkey of St. Kitts. Am J Med Genet B Neuropsychiatr Genet. 2007;144B(6):818-9.

8. Despain KE, McDonough JH, Mc- Monagle JD, McGinley MJ, Evans J. The toxicity of soman in the African green monkey (Chlorocebus aethiops). Toxicol Mech Methods. 2007;17(5):255-64.

9. Yalcin S, Mukai T, Kondo K, Ami Y, Okawa T, Kojima A, et al. Experimental infection of cynomolgus and African green monkeys with human herpesvirus 6. J Gen Virol. 1992;73 (Pt 7):1673-7.

10. Kaliste E. The welfare of laboratory animals. Dordrecht: Springer; 2007.

11. Hickman DL, Swan M. Use of a body condition score technique to assess health status in a rat model of polycystic kidney disease. J Am Assoc Lab Anim Sci. 2010;49(2):155-9.

12. Bayne K, Turner PV. Laboratory Animal Welfare. San Diego: Elsevier; 2014.

13. Terranova CJ, Cofman BS. Body weight of wild and captive lemurs. Zoo Biol. 1997;16:17-30.

14. Ford SM, Davis LC. Systematics and body size: Implications for feeding adaptations in New World monkeys. Am J Phys Anthropol. 1992;88(4):415-68.

15. Mazet JK, Gardner IA, Jessup DA, Lowenstine LJ, Boyce WM. Evaluation of changes in hematologic and clinical biochemical values after exposure to petroleum products in mink (Mustela vison) as a model for assessment of sea otters (Enhydra lutris). Am J Vet Res. 2000;61(10):1197-203.

16. Trumble SJ, Castellini MA, Mau TL, Castellini JM. Dietary and seasonal influences on blood chemistry and hematology in captive harbor seals. Mar Mamm Sci. 2006;22:104-123.

17. Farah IO, Ngotho M, Kariuki T, Jeneby M, Irura L, Maina N, et al. Animal models of tropical human diseases. In: Hau J, van Hoosier G, editors. Handbook of laboratory animal science. 2nd edition. Volume III. New York: CRC Press; 2005. p. 169-224.

18. Whalan EJ. A Toxicologist’s Guide to Clinical Pathology in Animals. Dordrecht: Springer; 2015.

19. Weingand K, Brown G, Hall R, Davies D, Gossett K, Neptun D, et al. Harmonization of animal clinical pathology testing in toxicity and safety studies. The Joint Scientific Committee for International Harmonization of Clinical Pathology Testing. Fundam Appl Toxicol. 1996;29(2):198-201.

20. Suleman MA, Wango E, Sapolsky RM, Odongo H, Hau J. Physiologic manifestations of stress from capture and restraint of free-ranging male African green monkeys (Cercopithecus aethiops). J Zoo Wildl Med. 2004;35(1):20-4.

21. de Neef KJ, Nieuwenhuijsen K, Lammers AJ, Degen AJ, Verbon F. Blood variables in adult stumptail macaques (Macaca arctoides) living in a captive group: annual variability. J Med Primatol. 1987;16(4):237-47.

22. Suleman MA, Wango E, Sapolsky RM, Odongo H, Hau J. Physiologic manifestations of stress from capture and restraint of free-ranging male African green monkeys (Cercopithecus aethiops). J Zoo Wildl Med. 2004;35:20-4.

23. Casacó A, Beausoleil I, Gonzalez B, Luaces P, León A, Arteaga ME, et al. Hematological, biochemical, respiratory, cardiovascular and electroneurophysiological parameters in African green monkeys (Cercopithecus aethiops sabaeus). Its use in nonclinical toxicological studies. J Med Primatol. 2010;39;177-86.

24. Chamanza R, Marxfeld HA, Blanco AI, Naylor SW, Bradley AE. Incidences and range of spontaneous findings in control cynomolgus monkeys (Macaca fascicularis) used in toxicity studies. Toxicol Pathol. 2010;38:642-57.

25. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015. A systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3(4):524-48.

26. MINSAP. Anuario estadístico de Salud. La Habana: Minsap; 2016.

27. Vector-borne diseases. understanding the environmental, human health, and ecological connections, Workshop Summary Washington (DC). Washington: National Academies Press (US); Institute of Medicine (US) Forum on Microbial Threats; 2008.

28. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504-7.

29. Hiyaoka A, Yoshida T, Cho F, Goto N. Growth curves of body weight changes in laboratory-bred female African green monkeys (Cercopithecus aethiops). Jikken Dobutsu. 1989;38(3):239-44.

30. Turner TR, Anapol F, Jolly CJ. Body weights of adult Vervet monkeys (Cercopithecus aethiops) at four sites in Kenya. Folia Primatol (Basel). 1994;63(3):177-9.

31. Kagira JM, Ngotho M, Thuita JK, Maina NW, Hau J: Hematological changes in vervet monkeys (Chlorocebus aethiops) during eight months’ adaptation to captivity. Am J Primatol. 2007;69(9):1053-63.

32. Sato A, Fairbanks LA, Lawson T, Lawson GW. Effects of age and sex on hematologic and serum biochemical values of vervet monkeys (Chlorocebus aethiops sabaeus). Contemp Top Lab Anim Sci. 2005;44(1):29-34.

33. Demyanets S, Wojta J. Sex differences in effects and use of anti-inflammatory drugs. In: Regitz-Zagrosek V (editor). Sex and gender differences in pharmacology. Handbook of Experimental Pharmacology. Dordrecht: Springer; 2012; p. 443-72.

34. Riviello MC, Wirz A: Haematology and blood chemistry of Cebus apella in relation to sex and age. J Med Primatol. 2001;30(6):308-12.

35. Liddie S, Goody RJ, Valles R, Lawrence MS. Clinical chemistry and hematology values in a Caribbean population of African green monkeys. J Med Primatol. 2010;39(6):389-98.

36. Pierre PJ, Sequeira MK, Corcoran CA, Blevins MW, Gee M, Laudenslager ML, Bennett AJ. Hematological and serum biochemical indices in healthy bonnet macaques (Macaca radiata). J Med Primatol. 2011;40(5):287-93.

37. Xie L, Xu F, Liu S, Ji Y, Zhou Q, Wu Q, et al. Age- and sex-based hematological and biochemical parameters for Macaca fascicularis. PLoS One. 2013;8(6):648-92.

38. Khan SH, Masood U, Hanif MS, Bokhari SORS, Khan MJ. Effect of age and gender on blood lipids and glucose. Rawal Med J. 2012;37(4):344-7.

39. Smith CP, Williams AJK, Thomas JM, Archibald HR, Algar VD, Bottazzo GF, et al. The pattern of basal and stimulated insulin responses to intravenous glucose in first degree relatives of type 1 (insulin-dependent) diabetic children and unrelated adults aged. 5 to 50 years. Diabetologia. 1988;31(7):430-4.

40. Khan SH, Masood U, Hanif MS, Bokhari SORS, Khan MJ. Effect of age and gender on blood lipids and glucose. Rawal Med J. 2012;37:344-7.

41. Loeb WF. The nonhuman primate. In: The Clinical Chemistry of Laboratory Animals. 1999. Loeb, Quimby (eds), 2nd ed. Philadelphia: Taylor and Francis; p. 145-62.

42. Veering BT, Burm AG, Souverijn JH, Serree JM, Spierdijk J. The effect of age on serum concentrations of albumin and alpha 1-acid glycoprotein. Br J Clin Pharmacol. 1990;29(2):201-6.

43. Ganong WF. Circulating body fluids. In: Foltin, Nogueira, Ransom & Sheinis (eds). Review of Medical Physiology. 20th ed. New York: McGraw-Hill Companies, Inc.; 2001. p. 499-527.

44. Izard MK, Heath SJ, Hayes Y, Simons EL. Hematology, serum chemistry values and rectal temperatures of adult greater galagos (Galago garnettii and G. crassicaudatus). J Med Primatol. 1991;20(3):117-21.

45. Hambleton P, Harris-Smith PW, Baskerville A, Bailey NE, Pavey KJ. Normal values for some whole blood and serum components of grivet monkeys (Cercopithecus aethiops). Lab Anim. 1979;13(2):87-91.

46. Nakano M, Mizuno T, Gotoh S. Accumulation of cardiac lipofuscin in crabeating monkeys (Macaca fasicularis): the same rate of lipofuscin accumulation in several species of primates. Mech Ageing Dev. 1993;66(3):243-8.

47. Nakano M, Mizuno T, Gotoh S. Accumulation of cardiac lipofuscin in mammals: correlation between sexual maturation and the first appearance of lipofuscin. Mech Ageing Dev. 1990;52(1):93-106.

48. Nakano M, Oenzil F, Mizuno T, Gotoh S. Age-related changes in the lipofuscin accumulation of brain and heart. Gerontology. 1995;41(2):69-79.

49. Clarkson TB, Lehner ND, Wagner WD, St Clair RW, Bond MG, Bullock BC. A study of atherosclerosis regression in Macaca mulatta. I. Design of experiment and lesion induction. Exp Mol Pathol. 1979;30(3):360-85.

50. Trillo AA, Prichard RW. Early endothelial changes in experimental primate atherosclerosis. Lab Invest. 1979;41(4):294-302.

51. Clarkson TB. Nonhuman primate models of atherosclerosis. Lab Anim Sci. 1998;48(6):569-72.

52. Trigo TFJ. Inmunopatología. In: Trigo Tavera FJ, Valero Elizondo G (editors). Patología General Veterinaria. 3era Edición. Ciudad de México: UNAM. 2014; p. 278.

53. Ito T, Chatani F, Sasaki S, Ando T, Miyajima H. Spontaneous lesions in cynomolgus monkeys used in toxicity studies. Jikken Dobutsu. 1992;41(4):455-69.

54. Andrade MC, Marchevsky RS. Histopathologic findings of pulmonary acariasis in a rhesus monkeys breeding unit Rev Bras Parasitol Vet. 2007;16(4):229-34.

55. Chamanza R, Marxfeld HA, Blanco AI, Naylor SW, Bradley AE. Incidences and range of spontaneous findings in control Cynomolgus monkeys (Macaca fascicularis) used in toxicity studies. Toxicol Pathol. 2010;38(4):642-57.

56. Greaves P. Digestive System. In: Greaves P. Histopathology of preclinical toxicity studies. Interpretation and relevance in Drug Safety Evaluation. Second Edition. New York: Elsevier Science; 2000. p. 456-9.

57. Zanzani SA, Gazzonis AL, Epis S, Manfredi MT. Study of the gastrointestinal parasitic fauna of captive non-human primates (Macaca fascicularis). Parasitol Res. 2016;115(1):307-12.

58. Marr-Belvin KA, Bailey CC, Heather L, Knight LH, Klumpp AS, Westmoreland VS, Miller DA. Ovarian pathology in rhesus macaques: A 12-year retrospective. J Med Primatol. 2010;39(3):170-6.

59. Cline JM, Wood CE, Vidal JD, Tarara RP, Buse E, Weinbauer GF, et al. Selected background findings and interpretation of common lesions in the female reproductive system in macaques. Toxicol Pathol. 2008;36(7):142-63.

60. Kim SW, Lee YH, Lee SR, Kim KM, Lee YJ, Jung KJ, et al. Bilateral ovarian cysts originating from rete ovarii in an African green monkey (Cercopithecus aethiops). J Vet Med Sci. 2012;74(9):1229-32.

61. Bennett BT; Abee CR, Henrickson R. Nonhuman Primates in Biomedical Research. Diseases. San Diego: Academic Press; 1998.

62. Rodríguez MR, Baluja IB, Bermúdez S. Patologías benignas de la próstata: prostatitis e hiperplasia benigna. Rev Biomed. 2007;18:47-59.

63. Halstead SB, Shotwell H, Casals J. Studies on the pathogenesis of dengue infection in monkeys. I. Clinical laboratory responses to primary infection. J Infect Dis. 1973;128(1):7-14.

64. Freire M, Marchevsky R, Almeida L, Yamamura A, Caride E, Brindeiro P, et al. Wild dengue virus types 1, 2 and 3 viremia in rhesus monkeys. Mem Inst Oswaldo Cruz. 2007;102(2):203-8.

65. Bernardo L, Izquierdo A, Alvarez M, Rosario D, Prado I, López C, et al. Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates. Antiviral Res. 2008;80(2):194-9.

66. Althouse BM, Durbin AP, Hanley KA, Halstead SB, Weaver SC, Cummings DA. Viral kinetics of primary dengue virus infection in non-human primates: a systematic review and individual pooled analysis. Virology. 2014;452-453:237-46.

67. Onlamoon N, Noisakran S, Hsiao HM, Duncan A, Villinger F, Ansari AA, Perng GC. Dengue virus– induced hemorrhage in a nonhuman primate model. Blood. 2010;115(9):1823-34.

68. Martínez E. Dengue. Estudos Avancados. 2008;22(64):33-52.

69. Samanta J, Sharma V. Dengue and its effects on liver. World J Clin Cases. 2015;3(2):125-31.

70. Sun W, Eckels KH, Putnak JR, Lyons AG, Thomas SJ, Vaughn DW, et al. Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines. J Infect Dis. 2013;207(5):700-8.

71. Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, Ratterree M, et al. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol. 2000;74(12):5477-85.

72. Lam NP, Neumann AU, Grech DW, Whiley TE, Perelson AS, Layden TJ. Dose dependent acute clearance of hepatitis C genotype 1 with interferon alfa. Hepatology. 1997;26(1):226-31.

73. Bocci V. Pharmacokinetics of interferons and routes of administration. In: Baron S, Coppenhaver DH, Dianzani F, editors. Interferon: principles and medical applications. Galveston: University of Texas Medical Branch; 1992.p. 417-25.

74. Registro Sanitario HeberPAG (Combinación de interferón alfa 2b humano recombinante e interferón gamma humano recombinante). B-08-039-L03 (3MUI); B- 08-040-L03 (10MUI). 2008.

75. Registro Sanitario HeberFERON (Interferón alfa 2b hu-rec + Interferón gamma hu-rec). B-16- 156-L03. 2016.

76. García-Vega Y, García I, Collazo SE, Santely EE, Cruz A, Tuero AD, et al. Pharmacokinetic and pharmacodynamics characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial. BMC Pharmacol Toxicol. 2012;13(20): 2050-6511.

77. García I, Hernández I, Díaz A, González CA, Pérez S, García Y, et al. Pharmacokinetic and pharmacodynamics characterization of a novel formulation containing co-formulated interferons alpha- 2b and gamma in healthy male volunteers. BMC Pharmacol Toxicol. 2016;17:58.

78. Rojas R, Duncan Y, Gómez CG, Ramírez LK, Lázaro G, Hernández R, et al. Administración del HeberFERON en el carcinoma basocelular palpebral a propósito de 2 casos. Bionat. 2016;1(2):71-4.

79. Felger JC, Alagbe O, Hu F, Mook D, Freeman AA, Sanchez MM, et al. Effects of interferon- alpha on Rhesus monkeys: A nonhuman primate model of cytokine-induced depression. Biol Psychiatry. 2007;62(11):1324-33.

80. Sajjad SF, Ahmed Wu, Arif A, Alam SE, Waquar J. Weight loss with interferon and ribavirin therapy in chronic hepatitis C patients. J Pak Med Assoc. 2012;62(11):1229-32.

81. Anasagasti L, Garcia Y, Barcelona S, Lopez P, Bello I. Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study, BMC Cancer. 2009; 9:262.

82. Schellekens H. The toxicity of human interferons in nonhuman primates. In: TC Merrigans, RM Friedman (eds). Interferons. New York: Academy Press; 1982.

83. Downing JF, Taylor MW, Wei KM, Elizondo RS. In vivo hyperthermia enhances plasma antiviral activity and stimulates peripheral lymphocytes for increased synthesis of interferongamma. J Interferon Res. 1987;7(2):185-93.

84. Perrillo RP. Chronic hepatitis B: problem patients (including patients with decompensated disease). J Hepatol. 1995;22(1):45-8.

85. Rodríguez JL, Valenzuela C, Marín N, Ferrero J, Ducongé J, Castillo R, et al. Comparative pharmacokinetics and pharmacodynamics of two recombinant human Interferon alpha- 2b formulations administered intramuscularly in healthy male volunteers. Biotecnol Apl. 2000;17:166-70.

86. Registro Sanitario HeberPAG (Combinación de interferón alfa 2b humano recombinante e interferón gamma humano recombinante). B-08-039-L03 (3MUI); B- 08-040-L03 (10MUI). 2008.

87. Registro Sanitario HeberFERON (Interferón alfa 2b hu-rec + Interferón gamma hu-rec). B-16-156-L03. 2016.

88. Limdi JK, Hyde GM. Evaluation of abnormal liver function tests. Postgrad Med J. 2016;92(1086):223-34.

89. Inker LA, Fan L, Levey AS. Assessment of renal function. In: Johnson RJ, Feehally J, Floege J. Comprehensive Clinical Nephrology. 5th ed. Philadelphia, PA: Elsevier Saunders; 2015. p. 30-8.

90. Kamba T, DM McDonald. Adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96(12):1788-95.

91. Genentech. Avastin. 2019 (cited 2019 October 16). Available from: http://www. gene.com/patients/medicines/avastin.

92. Gavilondo JV, Hernández-Bernal F, Ayala-Ávila M, de la Torre AV, de la Torre J, Morera-Díaz Y, et al. CENTAURO Group of Investigators. Specific active immunotherapy with a VEGF vaccine in patients withadvanced solid tumors. Results of the CENTAURO antigen dose escalation phase I clinical trial. Vaccine. 2014;32(19):2241-50.

93. Wentink M, Verheul H, Griffioen A, Schafer K, McPherson S, Early R, et al. A safety and immunogenicity study of immunization with hVEGF26-104/ RFASE in cynomolgus monkeys. Vaccine. 2018;36:2025-32.

94. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int. 2004;65(6):2003-17.

95. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061-8.

96. Morgan SJ, Elangbam CS, Berens S, Janovitz E, Vitsky A, Zabka T, et al. Use of animal models of human disease for nonclinical safety assessment of novel pharmaceuticals. Toxicol Pathol. 2013;41(3):508-18.